Several of the world’s largest pharmaceutical companies have notified a congressional committee that they will not open new clinical trial sites in China’s Xinjiang region or at hospitals affiliated with the Chinese military.
The disclosure came from the House Select Committee on China, which last June began investigating Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb. The panel cited concerns over intellectual property risks, military entanglements, and ethical standards at trial sites in sensitive regions.
All five companies said they would not initiate new clinical studies at facilities tied to the People’s Liberation Army, the military arm of the Chinese Communist Party. In letters to the drugmakers, the House committee expressed growing concern over potential security risks.
Also Read
- Experimental Compound Boosts Energy Expenditure to Burn Fat Without Losing Muscle
- Potential Blood Test Could Detect CTE in Living Patients
- Merck Partners with Isomorphic Labs to Accelerate Drug Discovery for Key Oncology Target
- Pediatric Imaging Associated with Dose-Dependent Brain Tumor Risk in Children and Adolescents


